{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:57Z","timestamp":1792719897030,"version":"4.5.0"},"reference-count":47,"publisher":"Endocrinology Research Centre","issue":"6","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Studies of recent decades show a steady increase in the average life expectancy of a person, and women in particular. The World Health Organization predicts a four-fold increase in the number of women over 70 by 2030, and many of them over the age of 45 may face menopausal problems. Menopause is a physiological state in a woman\u2019s life, during which, against the background of age-related changes, there is a gradual decrease and shutdown of ovarian function and the cessation of estrogen production. Genitourinary syndrome occurs in every third woman in this period. Estriol is the main estrogen that specifically addresses problems associated with estrogen deficiency: dyspareunia, dryness and itching in the vagina and lower genitourinary tract, urinary incontinence, moderate urinary incontinence, and recurrent vulvovaginitis and cystitis. Vulvovaginal dystrophy in women of the older age group is a multidisciplinary problem at the intersection of gynecology, urology and dermatology, which can and should be solved to prevent more severe gynecological and urological pathologies.<\/jats:p>","DOI":"10.14341\/probl13198","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T12:20:40Z","timestamp":1674735640000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":6,"title":["The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women"],"prefix":"10.14341","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-0020","authenticated-orcid":true,"given":"E. N.","family":"Andreeva","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre; Evdokimov Moscow State University of Medicine and Dentistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-0254","authenticated-orcid":true,"given":"E. V.","family":"Sheremetyeva","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5458","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Andreeva EN, Sheremetyeva EV. Mental aspects and fat metabolic disturbance in menopause. Obstetrics and gynecology. 2019;(9):165-172. (In Russ.). doi: https:\/\/doi.org\/10.18565\/aig.2019.9.165-172","DOI":"10.18565\/aig.2019.9.165-172"},{"key":"ref2","unstructured":"Tkacheva ON, Runikhina NK, Kotovskaia IuV, et al. Metodicheskie rekomendatsii \u00abProfilaktika prezhdevremennogo stareniia u zhenshchin\u00bb. Moscow: 2018. (In Russ.)."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. 2009;12(4):279-285. doi: https:\/\/doi.org\/10.1080\/13697130902814751","DOI":"10.1080\/13697130902814751"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Panay N, Palacios S, Bruyniks N, et al. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124(4):55-61. doi: https:\/\/doi.org\/10.1016\/j.maturitas.2019.03.013","DOI":"10.1016\/j.maturitas.2019.03.013"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286-291. doi: https:\/\/doi.org\/10.1080\/13697137.2018.1446930","DOI":"10.1080\/13697137.2018.1446930"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61(3):508-516. doi: https:\/\/doi.org\/10.1097\/GRF.0000000000000380","DOI":"10.1097\/GRF.0000000000000380"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Vieira-Baptista P, Donders G, Margesson L, et al. Diagnosis and management of vulvodynia in postmenopausal women. Maturitas. 2018;(108):84-94. doi: https:\/\/doi.org\/10.1016\/j.maturitas.2017.11.003","DOI":"10.1016\/j.maturitas.2017.11.003"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Calleja-Agius J, Brincat MP. The urogenital system and the menopause. Climacteric. 2015;18(S1):18-22. doi: https:\/\/doi.org\/10.3109\/13697137.2015.1078206","DOI":"10.3109\/13697137.2015.1078206"},{"key":"ref9","unstructured":"Rossiiskoe obshchestvo urologov. Klinicheskie rekomendatsii. Nederzhanie mochi u vzroslykh. Moscow: MZ RF; 2020. (In Russ.)."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Krychman M, Graham S, Bernick B, et al. The women\u2019s EMPOWER survey: women\u2019s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425-433. doi: https:\/\/doi.org\/10.1016\/j.jsxm.2017.01.011","DOI":"10.1016\/j.jsxm.2017.01.011"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-day impact of vaginal aging questionnaire. Menopause. 2015;22(2):144-154. doi: https:\/\/doi.org\/10.1097\/GME.0000000000000281","DOI":"10.1097\/GME.0000000000000281"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Angelou K, Grigoriadis T, Diakosavvas M, et al. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020;12(4):e7586. doi: https:\/\/doi.org\/10.7759\/cureus.7586","DOI":"10.7759\/cureus.7586"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Angelou K, Grigoriadis T, Diakosavvas M, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi: https:\/\/doi.org\/10.1097\/GME.0000000000001609","DOI":"10.1097\/GME.0000000000001609"},{"key":"ref14","unstructured":"Apolikhina IA, Iureneva SV, Malyshkina DA. Genitourinarnyi menopauzal\u2019nyi sindrom: sovremennye podkhody k diagnostike i lecheniiu. Obstetrics and gynecology. 2020;(12):4-8. (In Russ.)."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mension E, Alonso I, Castelo-Branco C. Genitourinary Syndrome of Menopause: Current Treatment Options in Breast Cancer Survivors \u2013 Systematic Review. Maturitas. 2021;143(9):47-58. doi: https:\/\/doi.org\/10.1016\/j.maturitas.2020.08.010","DOI":"10.1016\/j.maturitas.2020.08.010"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Li B, Duan H, Chang Y, Wang S. Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients. Pharmacol Res. 2021;164(9):105360. doi: https:\/\/doi.org\/10.1016\/j.phrs.2020.105360","DOI":"10.1016\/j.phrs.2020.105360"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women\u2019s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi: https:\/\/doi.org\/10.3109\/13697137.2015.1129166","DOI":"10.3109\/13697137.2015.1129166"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Punnonen R, Vilska S, Gr\u00f6nroos M, Rauramo L. The vaginal absorption of oestrogens in postmenopausal women. Maturitas. 1980;2(4):321-326. doi: https:\/\/doi.org\/10.1016\/0378-5122(80)90034-1","DOI":"10.1016\/0378-5122(80)90034-1"},{"key":"ref19","unstructured":"Reed-Kane D. Natural hormone replacement therapy: What it is and what consumers really want. Int J Pharmaceut Compounding. 2001;5(5):332-335."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Khan IU, Serra CA, Anton N, et al. Microfluidic conceived Trojan microcarriers for oral delivery of nanoparticles. Int J Pharm. 2015;493(1-2):7-15. doi: https:\/\/doi.org\/10.1016\/j.ijpharm.2015.06.028","DOI":"10.1016\/j.ijpharm.2015.06.028"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Anton N, Jakhmola A, Vandamme TF. Trojan microparticles for drug delivery. Pharmaceutics. 2012;4(1):1-25. doi: https:\/\/doi.org\/10.3390\/pharmaceutics4010001","DOI":"10.3390\/pharmaceutics4010001"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Li X, Anton N, Ta TM, et al. Microencapsulation of nanoemulsions: novel Trojan particles for bioactive lipid molecule delivery. Int J Nanomedicine. 2011;(6):1313-1325. doi: https:\/\/doi.org\/10.2147\/IJN.S20353","DOI":"10.2147\/IJN.S20353"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Prilepskaya VN, Nazarenko EG. Estriol in therapy of various gynecological diseases. Medical Council. 2017;(2):8-13. (In Russ.). doi: https:\/\/doi.org\/10.21518\/2079-701X-2017-2-8-13","DOI":"10.21518\/2079-701X-2017-2-8-13"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Vooijs GP, Geurts TBP. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol. 1995;62(1):101-106. doi: https:\/\/doi.org\/10.1016\/0301-2115(95)02170-C","DOI":"10.1016\/0301-2115(95)02170-C"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ali ES, Mangold C, Peiris AN. Estriol: emerging clinical benefits. Menopause. 2017;24(9):1081-1085. doi: https:\/\/doi.org\/10.1097\/GME.0000000000000855","DOI":"10.1097\/GME.0000000000000855"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Capobianco G, Donolo E, Borghero G, et al. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2012;285(2):397-403. doi: https:\/\/doi.org\/10.1007\/s00404-011-1955-1","DOI":"10.1007\/s00404-011-1955-1"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG An Int J Obstet Gynaecol. 2000;107(8):1029-1034. doi: https:\/\/doi.org\/10.1111\/j.1471-0528.2000.tb10408.x","DOI":"10.1111\/j.1471-0528.2000.tb10408.x"},{"key":"ref28","unstructured":"\u0424\u0435\u0434\u0435\u0440\u0430\u043b\u044c\u043d\u044b\u0439 \u0437\u0430\u043a\u043e\u043d \u043e\u0442 12.04.2010 N 61-\u0424\u0417 (\u0440\u0435\u0434. \u043e\u0442 14.07.2022) \u00ab\u041e\u0431 \u043e\u0431\u0440\u0430\u0449\u0435\u043d\u0438\u0438 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u0441\u0440\u0435\u0434\u0441\u0442\u0432\u00bb. Federal Law of Russian Federation 12.04.2010 N 61-FZ (red. ot 14.07.2022) \u00abOb obrashchenii lekarstvennykh sredstv\u00bb (In Russ.)."},{"key":"ref29","unstructured":"Rossiiskoe obshchestvo akusherov-ginekologov. Klinicheskie rekomendatsii. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Moscow: MZ RF; 2021. (In Russ.)."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Lumsden MA, Davies M, Sarri G. Diagnosis and Management of Menopause. JAMA Intern Med. 2016;176(8):1205. doi: https:\/\/doi.org\/10.1001\/jamainternmed.2016.2761","DOI":"10.1001\/jamainternmed.2016.2761"},{"key":"ref31","unstructured":"Vzaimozameniaemye lekarstvennye preparaty (p. 4 ch. 4 st. 3 Federal\u2019nogo zakona ot 27.12.2019 \u2116 475-FZ, p. 8 postanovleniia Pravitel\u2019stva ot 05.09.2020 \u2116 1360) (In Russ.)."},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-522. doi: https:\/\/doi.org\/10.3109\/13697137.2010.522875","DOI":"10.3109\/13697137.2010.522875"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452-461. doi: https:\/\/doi.org\/10.1097\/GME.0000000000000768","DOI":"10.1097\/GME.0000000000000768"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Vetuschi A, D\u2019Alfonso A, Sferra R, et al. Changes in muscularis propria of anterior vaginal wall in women with pelvic organ prolapse. Eur J Histochem. 2016;60(1):33-38. doi: https:\/\/doi.org\/10.4081\/ejh.2016.2604","DOI":"10.4081\/ejh.2016.2604"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019;20(7):821-835. doi: https:\/\/doi.org\/10.1080\/14656566.2019.1574752","DOI":"10.1080\/14656566.2019.1574752"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Traish AM, Vignozzi L, Simon JA, et al. Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause. Sex Med Rev. 2018;6(4):558-571. doi: https:\/\/doi.org\/10.1016\/j.sxmr.2018.03.005","DOI":"10.1016\/j.sxmr.2018.03.005"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Pessina MA, Hoyt RF, Goldstein I, Traish AM. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology. 2006;147(1):61-69. doi: https:\/\/doi.org\/10.1210\/en.2005-0870","DOI":"10.1210\/en.2005-0870"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Berman JR, Almeida FG, Jolin J, et al. Correlation of androgen receptors, aromatase, and 5-\u03b1 reductase in the human vagina with menopausal status. Fertil Steril. 2003;79(4):925-931. doi: https:\/\/doi.org\/10.1016\/S0015-0282(02)04923-3","DOI":"10.1016\/S0015-0282(02)04923-3"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401-2412. doi: https:\/\/doi.org\/10.1111\/jsm.13045","DOI":"10.1111\/jsm.13045"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Merritt P, Stangl B, Hirshman E, Verbalis J. Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short-term memory in post-menopausal women. Brain Res. 2012;(1483):54-62. doi: https:\/\/doi.org\/10.1016\/j.brainres.2012.09.015","DOI":"10.1016\/j.brainres.2012.09.015"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women. Menopause. 2011;18(1):30-43. doi: https:\/\/doi.org\/10.1097\/gme.0b013e3181e195a6","DOI":"10.1097\/gme.0b013e3181e195a6"},{"key":"ref42","unstructured":"Rossiiskoe obshchestvo akusherov-ginekologov. Klinicheskie rekomendatsii. Vypadenie zhenskikh polovykh organov. Moscow: MZ RF; 2021. (In Russ.)."},{"key":"ref43","unstructured":"Rossiiskoe obshchestvo urologov. Klinicheskie rekomendatsii. Tsistit u zhenshchin. Moscow: MZ RF; 2021. (In Russ.)."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide Maturitas 2021;148:55-61. Available from: https:\/\/emas-online.org\/emas-clinical-guides\/","DOI":"10.1016\/j.maturitas.2021.04.005"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Griesser H, Skonietzki S, Fischer T, et al. Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebocontrolled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas. 2012;71(4):360-368. doi: https:\/\/doi.org\/10.1016\/j.maturitas.2011.12.022","DOI":"10.1016\/j.maturitas.2011.12.022"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Rueda C, Osorio AM, Avellaneda AC, et al. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20(4):321-330. doi: https:\/\/doi.org\/10.1080\/13697137.2017.1329291","DOI":"10.1080\/13697137.2017.1329291"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(11). doi: https:\/\/doi.org\/10.1002\/14651858.CD001500.pub3","DOI":"10.1002\/14651858.CD001500.pub3"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13198\/10391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T12:21:47Z","timestamp":1674735707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,1,20]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13198","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,30]]}}}